9th Circ. Upholds Ex-InterMune CEO's Fraud Conviction

Law360, New York (March 5, 2013, 5:16 PM EST) -- The former CEO of InterMune Inc. on Monday failed to persuade the Ninth Circuit to overturn his fraud conviction after the appeals court backed a jury's finding that his press release touting the drug Actimmune as a treatment for a deadly lung illness was intentionally misleading.

A three-judge panel found there was enough evidence that W. Scott Harkonen had falsely stated the results of a clinical trial in his August 2009 press release, affirming his September 2009 wire fraud conviction. The panel also said evidence sufficiently...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.